Somewhat Negative Press Coverage Somewhat Unlikely to Impact KemPharm (KMPH) Stock Price

News stories about KemPharm (NASDAQ:KMPH) have been trending somewhat negative recently, Accern Sentiment Analysis reports. The research group identifies positive and negative media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. KemPharm earned a coverage optimism score of -0.06 on Accern’s scale. Accern also gave media stories about the specialty pharmaceutical company an impact score of 44.2517130442225 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

Shares of KemPharm (NASDAQ:KMPH) remained flat at $$5.00 during trading on Friday. The company’s stock had a trading volume of 76,446 shares, compared to its average volume of 52,272. The company has a market cap of $73.28, a PE ratio of -1.89 and a beta of -1.09. The company has a debt-to-equity ratio of -1.92, a quick ratio of 7.56 and a current ratio of 7.56. KemPharm has a 12-month low of $2.45 and a 12-month high of $5.40.

A number of equities analysts have commented on the stock. Zacks Investment Research downgraded shares of KemPharm from a “buy” rating to a “hold” rating in a research report on Wednesday. ValuEngine upgraded shares of KemPharm from a “strong sell” rating to a “sell” rating in a research report on Sunday, December 31st. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $8.15.

In other news, EVP Daniel L. Cohen acquired 7,500 shares of the business’s stock in a transaction on Monday, November 27th. The stock was bought at an average price of $3.79 per share, for a total transaction of $28,425.00. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. 22.80% of the stock is currently owned by corporate insiders.

ILLEGAL ACTIVITY NOTICE: This piece was posted by Stock Observer and is the sole property of of Stock Observer. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of international trademark and copyright laws. The original version of this piece can be viewed at https://www.thestockobserver.com/2018/01/14/somewhat-negative-press-coverage-somewhat-unlikely-to-impact-kempharm-kmph-stock-price.html.

KemPharm Company Profile

KemPharm, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company’s product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP).

Insider Buying and Selling by Quarter for KemPharm (NASDAQ:KMPH)

Receive News & Ratings for KemPharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply